Dorff T, Horvath LG, Autio K, Bernard-Tessier A, et al. A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer. Clin Cancer Res 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-2978.
PMID: 38300720